Who is sponsoring NCT04460339?

NCT04460339 is sponsored by University Hospital, Caen.

What drugs are being tested in NCT04460339?

Interventions in NCT04460339: Swimming participants in the 25-km.

What condition does NCT04460339 study?

NCT04460339 studies Hypothermia Due to Cold Environment.

Is NCT04460339 still recruiting?

NCT04460339 is currently completed. Last updated 26 March 2025.

Last reviewed 2025-03-26 · How we verify

NCT04460339: THERMO25

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thermoregulation During a 25-km Open Water Race

Completed Last updated 26 March 2025

What this trial tests

trial testing Swimming participants in the 25-km in Hypothermia Due to Cold Environment in 24 participants. Completed in 3 June 2020.

Timeline

1 March 2019

Primary endpoint
26 May 2019

3 June 2020

Quick facts

Lead sponsor	University Hospital, Caen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	24
Start date	1 March 2019
Primary completion	26 May 2019
Estimated completion	3 June 2020
Sites	1 location across France

Drugs / interventions tested

Swimming participants in the 25-km

Conditions studied

Hypothermia Due to Cold Environment — all drugs for Hypothermia Due to Cold Environment →

Sponsor

University Hospital, Caen

Who can join

Adults 15 to 45, any sex, with Hypothermia Due to Cold Environment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open water swimming is a swimming discipline which takes place in outdoor water such as open oceans, lakes, and rivers. Elite swimmers are exposed to hypothermia when swimming in cold water, especially in long duration races, such as the 25-km race. The objective of this study is to evaluate the change in body core temperature in swimmers with continuous temperature monitoring during a 25-km race. The secondary objective is to identify the predictors of hypothermia and hypothermia-related drop-out.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Caen trials

Trials by the same sponsor.

NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04460339 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
Last refreshed: 26 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04460339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing